CoChat
Sign Up
Cited by 78Eosinophilic Disorders and SyndromesViral Infections and Immunology ResearchIgG4-Related and Inflammatory Diseases

The DOI matches its Crossref record.

Eosinophilic Myocarditis

Cheung, Christopher C., Constantine, Maggie, Ahmadi, Amir, Shiau, Carolyn, Chen, Luke Y.C.·2017·The American Journal of the Medical Sciences
DOI 10.1016/j.amjms.2017.04.002
Open this paper in CoChat — free account

Abstract

Persistent eosinophilia can cause cardiac tissue damage, typically in the form of eosinophilic myocarditis, whether the underlying cause is reactive, a clonal myeloid disorder, or idiopathic hypereosinophilic syndrome (HES). Eosinophilic myocarditis ranges from mild localized disease to multifocal widespread infiltrates associated with myocardial necrosis, thrombotic complications and endomyocardial fibrosis. Systemic treatment varies widely depending on the underlying cause, so thorough investigation and precise diagnosis are essential. Evaluation includes assessment for reactive causes of eosinophilia (vasculitis such as eosinophilic granulomatosis and polyangiitis or Churg-Strauss, parasitic infection, autoimmune disease, immunoglobulinG4-related disease, medications and other causes), genetic lesions characteristic of clonal myeloid disorders (platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and flow cytometry and molecular studies for the aberrant T cells characteristic of lymphocyte-variant HES . Patients with reactive eosinophilia require treatment for the underlying cause, such as antiparasitic therapy for helminthic infection or immunosuppression for eosinophilic granulomatosis and polyangiitis or Churg-Strauss. Those with a myeloid clone often benefit from the tyrosine kinase inhibitor imatinib. Steroids are the first-line treatment for idiopathic HES and lymphocyte-variant HES, and hydroxy…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjms.2017.04.002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 58

  1. Tefferi, 2006, Eosinophilia: secondary, clonal and idiopathic, Br J Haematol, 133, 468, 10.1111/j.1365-2141.2006.06038.x · DOI
  2. Long, 2016, A player and coordinator: the versatile roles of eosinophils in the immune system, Transfus Med Hemother, 43, 96, 10.1159/000445215 · DOI
  3. Gotlib, 2014, World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management, Am J Hematol, 89, 325, 10.1002/ajh.23664 · DOI
  4. Ogbogu, 2009, Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy, J Allergy Clin Immunol, 124, 10.1016/j.jaci.2009.09.022 · DOI
  5. Loeffler, 1936, Endocarditis parietalis fibroplastica mit blut-eosinphilie, ein eigenartiges krankheitshild, Schweiz Med Wochenschr, 66, 817
  6. Weller, 1994, The idiopathic hypereosinophilic syndrome, Blood, 83, 2759, 10.1182/blood.V83.10.2759.2759 · DOI · Paper page
  7. Ermens, 2003, Significance of elevated cobalamin (vitamin B12) levels in blood, Clin Biochem, 36, 585, 10.1016/j.clinbiochem.2003.08.004 · DOI
  8. Ogbogu, 2007, Cardiovascular manifestations of hypereosinophilic syndromes, Immunol Allergy Clin North Am, 27, 457, 10.1016/j.iac.2007.07.001 · DOI · Paper page
  9. Comarmond, 2013, Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort, Arthritis Rheum, 65, 270, 10.1002/art.37721 · DOI
  10. Moosig, 2013, A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients, Ann Rheum Dis, 72, 1011, 10.1136/annrheumdis-2012-201531 · DOI · Paper page
  11. Gotlib, 2015, World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management, Am J Hematol, 90, 1077, 10.1002/ajh.24196 · DOI
  12. Pardanani, 2004, FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia, Blood, 104, 3038, 10.1182/blood-2004-03-0787 · DOI
  13. Pardanani, 2006, FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature, Leuk Res, 30, 965, 10.1016/j.leukres.2005.11.011 · DOI
  14. Seguela, 2015, Eosinophilic cardiac disease: molecular, clinical and imaging aspects, Arch Cardiovasc Dis, 108, 258, 10.1016/j.acvd.2015.01.006 · DOI
  15. deMello, 1990, Cardiac localization of eosinophil-granule major basic protein in acute necrotizing myocarditis, N Engl J Med, 323, 1542, 10.1056/NEJM199011293232207 · DOI · Paper page
  16. Patella, 1996, Eosinophil granule proteins activate human heart mast cells, J Immunol, 157, 1219, 10.4049/jimmunol.157.3.1219 · DOI
  17. Moosig, 2013, A fatal attraction: eosinophils and the heart, Rheumatology (Oxford, England), 52, 587, 10.1093/rheumatology/kes420 · DOI
  18. Collins, 1995, Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo, J Exp Med, 182, 1169, 10.1084/jem.182.4.1169 · DOI
  19. Matthews, 1998, Eotaxin is required for the baseline level of tissue eosinophils, Proc Natl Acad Sci U S A, 95, 6273, 10.1073/pnas.95.11.6273 · DOI
  20. Diny, 2016, Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart, Eur J Immunol, 46, 2749, 10.1002/eji.201646557 · DOI · Paper page
  21. Cugno, 2014, Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis, PloS One, 9, e111862, 10.1371/journal.pone.0111862 · DOI
  22. Slungaard, 1993, Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease, J Clin Invest, 91, 1721, 10.1172/JCI116382 · DOI
  23. Galiuto, 1997, Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment, Mayo Clin Proc, 72, 603, 10.1016/S0025-6196(11)63564-7 · DOI
  24. Lim, 2013, Hypereosinophilic syndrome masquerading as a myocardial infarction causing decompensated heart failure, BMC Cardiovasc Disord, 13, 75, 10.1186/1471-2261-13-75 · DOI
  25. Al Ali, 2006, Eosinophilic myocarditis: case series and review of literature, Can J Cardiol, 22, 1233, 10.1016/S0828-282X(06)70965-5 · DOI
  26. Getz, 1991, Acute necrotizing eosinophilic myocarditis as a manifestation of severe hypersensitivity myocarditis. Antemortem diagnosis and successful treatment, Ann Intern Med, 115, 201, 10.7326/0003-4819-115-3-201 · DOI
  27. Chun, 2004, Images in cardiovascular medicine. Infiltrative eosinophilic myocarditis diagnosed and localized by cardiac magnetic resonance imaging, Circulation, 110, e19, 10.1161/01.CIR.0000135586.94417.3C · DOI
  28. Kuchynka, 2016, Current diagnostic and therapeutic aspects of eosinophilic myocarditis, BioMed Res Int, 2016, 2829583, 10.1155/2016/2829583 · DOI · Paper page
  29. Marmursztejn, 2013, Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients, Rheumatology (Oxford, England), 52, 642, 10.1093/rheumatology/kes155 · DOI
  30. Baandrup, 2012, Eosinophilic myocarditis, Herz, 37, 849, 10.1007/s00059-012-3701-2 · DOI
  31. Grimaldi, 2016, Tropical endomyocardial fibrosis: natural history, challenges, and perspectives, Circulation, 133, 2503, 10.1161/CIRCULATIONAHA.115.021178 · DOI
  32. Bochner, 2012, Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD), J Allergy Clin Immunol, 130, 587, 10.1016/j.jaci.2012.07.024 · DOI
  33. Klion, 2006, Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report, J Allergy Clin Immunol, 117, 1292, 10.1016/j.jaci.2006.02.042 · DOI
  34. Klion, 2015, How I treat hypereosinophilic syndromes, Blood, 126, 1069, 10.1182/blood-2014-11-551614 · DOI
  35. Chen, 2015, Polyclonal hyperviscosity syndrome in IgG4-related disease and associated conditions, Clin Case Rep, 3, 217, 10.1002/ccr3.201 · DOI
  36. Mahajan, 2014, IgG4-related disease, Annu Rev Pathol, 9, 315, 10.1146/annurev-pathol-012513-104708 · DOI
  37. Carruthers, 2017, IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: a comparative case series, Eur J Haematol, 98, 378, 10.1111/ejh.12842 · DOI
  38. Chen, 2015, Hallway consult: does this patient have IgG4-related disease?, Can Rheumatol Assoc J, 25, 26
  39. Hamano, 2001, High serum IgG4 concentrations in patients with sclerosing pancreatitis, N Engl J Med, 344, 732, 10.1056/NEJM200103083441005 · DOI
  40. Kamisawa, 2003, A new clinicopathological entity of IgG4-related autoimmune disease, J Gastroenterol, 38, 982, 10.1007/s00535-003-1175-y · DOI
  41. Wong, 2013, IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy, Eur J Haematol, 90, 250, 10.1111/ejh.12059 · DOI
  42. Carruthers, 2015, The diagnostic utility of serum IgG4 concentrations in IgG4-related disease, Ann Rheum Dis, 74, 14, 10.1136/annrheumdis-2013-204907 · DOI
  43. Carbajal, 2013, IgG4 related cardiac disease, Methodist DeBakey Cardiovasc J, 9, 230, 10.14797/mdcj-9-4-230 · DOI
  44. Simon, 1999, Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia, N Engl J Med, 341, 1112, 10.1056/NEJM199910073411503 · DOI
  45. Roufosse, 2007, Lymphocytic variant hypereosinophilic syndromes, Immunol Allergy Clin North Am, 27, 389, 10.1016/j.iac.2007.07.002 · DOI
  46. Lefevre, 2015, CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder, Haematologica, 100, 1086
  47. Pitini, 2004, Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report, Br J Haematol, 127, 477, 10.1111/j.1365-2141.2004.05206.x · DOI
  48. Garcia-Alvarez, 2010, Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib, Int J Cardiol, 139, e29, 10.1016/j.ijcard.2008.11.018 · DOI
  49. Wang, 2016, Eosinophilic myocarditis: characteristics, diagnostics and outcomes of a rare condition, Intern Med J, 46, 1104, 10.1111/imj.13176 · DOI
  50. Li, 2016, A case report of eosinophilic myocarditis and a review of the relevant literature, BMC Cardiovasc Disord, 15, 15, 10.1186/s12872-015-0003-7 · DOI
  51. Sohn, 2016, Eosinophilic myocarditis: case series and literature review, Asia Pac Allergy, 5, 123, 10.5415/apallergy.2015.5.2.123 · DOI
  52. Lefevre, 2014, The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype, Medicine (Baltimore), 93, 255, 10.1097/MD.0000000000000088 · DOI
  53. Carruthers, 2015, Rituximab for IgG4-related disease: a prospective, open-label trial, Ann Rheum Dis, 74, 1171, 10.1136/annrheumdis-2014-206605 · DOI
  54. Butterfield, 2012, Use of pegylated interferon in hypereosinophilic syndrome, Leuk Res, 36, 192, 10.1016/j.leukres.2011.09.026 · DOI
  55. Butterfield, 2005, Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis, Acta Haematol, 114, 26, 10.1159/000085560 · DOI
  56. Rothenberg, 2008, Treatment of patients with the hypereosinophilic syndrome with mepolizumab, N Engl J Med, 358, 1215, 10.1056/NEJMoa070812 · DOI
  57. Verstovsek, 2009, Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia, Clin Cancer Res, 15, 368, 10.1158/1078-0432.CCR-08-1302 · DOI
  58. Halaburda, 2006, Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript, Bone Marrow Transplant, 38, 319, 10.1038/sj.bmt.1705437 · DOI

Cited by

Sorted by citations

See all 78

Metadata

Authors
Cheung, C. C., Constantine, M., Ahmadi, A., Shiau, C., & Chen, L. Y. C.
Affiliations
  • University of British Columbia (CA)
  • Royal Columbian Hospital (CA)
Corresponding author
Chen, Luke Y.C.
ORCID
Venue
The American Journal of the Medical Sciences
Publisher
Elsevier BV
Published
2017-11
Volume
354
Issue
5
Pages
486-492
ISSN
0002-9629 (ISSN-L)
DOI
10.1016/j.amjms.2017.04.002
OpenAlex
W2605040104
Cited by
78
References
0
Citations by year
2026: 6 · 2025: 7 · 2024: 11 · 2023: 15 · 2022: 8 · 2021: 9 · 2020: 12 · 2019: 8 · 2018: 2
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The American Journal of the Medical Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
eosinophilic myocarditis, eosinophilia, idiopathic hypereosinophilic syndrome, reactive eosinophilia, eosinophilic granulomatosis with polyangiitis, endomyocardial fibrosis, imatinib, mepolizumab, IL-5, steroid-sparing therapy, hydroxyurea, interferon-alpha
MeSH terms
Humans, Myocarditis, Hypereosinophilic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eosinophilic Myocarditis. https://app.cochat.ai/papers/10.1016/j.amjms.2017.04.002
The paper
Cheung, C. C., Constantine, M., Ahmadi, A., Shiau, C., & Chen, L. Y. C. (2017). Eosinophilic Myocarditis. The American Journal of the Medical Sciences. https://doi.org/10.1016/j.amjms.2017.04.002